pomalidomide has been researched along with vorinostat in 6 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (vorinostat) | Trials (vorinostat) | Recent Studies (post-2010) (vorinostat) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 2,529 | 181 | 1,840 |
| Protein | Taxonomy | pomalidomide (IC50) | vorinostat (IC50) |
|---|---|---|---|
| Chain A, Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 0.95 | |
| Chain A, Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 0.95 | |
| Histone deacetylase 8 | Schistosoma mansoni | 1.3147 | |
| Histone deacetylase | Rattus norvegicus (Norway rat) | 0.165 | |
| Gli1 | Mus musculus (house mouse) | 2.23 | |
| nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | 0.7472 | |
| cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | 1.55 | |
| Histone deacetylase 1 | Mus musculus (house mouse) | 0.1121 | |
| Histone deacetylase 3 | Homo sapiens (human) | 0.3382 | |
| Bromodomain-containing protein 4 | Homo sapiens (human) | 0.2644 | |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.0382 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.456 | |
| Tubulin alpha-1A chain | Sus scrofa (pig) | 1.5 | |
| Tubulin beta chain | Sus scrofa (pig) | 1.5 | |
| Albumin | Homo sapiens (human) | 0.1072 | |
| Leukotriene A-4 hydrolase | Homo sapiens (human) | 4.66 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 0.0903 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.011 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.24 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.1582 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.053 | |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | 0.116 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
| Leukotriene A-4 hydrolase | Mus musculus (house mouse) | 6.15 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.042 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.13 | |
| Delta-type opioid receptor | Homo sapiens (human) | 7.2 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 7.2 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.6096 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.086 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.322 | |
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.1 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.2701 | |
| Histone deacetylase 1 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase | Rattus norvegicus (Norway rat) | 0.165 | |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | 0.07 | |
| Renin | Macaca fascicularis (crab-eating macaque) | 0.067 | |
| Histone deacetylase 3 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 1 | |
| Histone deacetylase | Plasmodium falciparum 3D7 | 0.1 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.6115 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.3746 | |
| HD2 type histone deacetylase HDA106 | Zea mays | 0.2227 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.4211 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.5235 | |
| Carboxypeptidase B2 | Homo sapiens (human) | 0.362 | |
| Histone deacetylase 7 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase 6 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase 4 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.9141 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.2634 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.5614 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.5926 | |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0945 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.0905 | |
| Histone deacetylase 6 | Mus musculus (house mouse) | 0.3742 | |
| Histone deacetylase | Zea mays | 0.029 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barinka, C; Leisten, ED; Li, Z; Liu, J; Novakova, Z; Smith, KA; Tang, W; Wu, H; Xie, H; Yang, K; Zhang, Z | 1 |
| Hata, H | 1 |
| Stewart, AK | 1 |
| Orlowski, RZ | 1 |
| Kuroda, J | 1 |
| Anderson, KC; Cottini, F; Gorgun, G; Hideshima, T; Jakubikova, J; Mimura, N; Munshi, NC; Ohguchi, H; Richardson, PG; Tai, YT | 1 |
3 review(s) available for pomalidomide and vorinostat
| Article | Year |
|---|---|
[Development of novel agents for multiple myeloma; now and the future].
Topics: Animals; Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Benzoquinones; Benzylamines; Clinical Trials as Topic; Cyclams; Drug Discovery; Drug Therapy, Combination; Heterocyclic Compounds; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Molecular Targeted Therapy; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Thalidomide; Vorinostat | 2011 |
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat | 2013 |
[Current status of clinical trials of novel agents for multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Approval; Drug Discovery; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lactones; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Pyrroles; Thalidomide; Vorinostat | 2014 |
3 other study(ies) available for pomalidomide and vorinostat
| Article | Year |
|---|---|
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Development; HeLa Cells; Hep G2 Cells; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; MCF-7 Cells; Multiple Myeloma | 2019 |
Novel therapeutics in multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide; Vorinostat | 2012 |
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Immunomodulation; In Vitro Techniques; Lenalidomide; Multiple Myeloma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Thalidomide; Transfection; Vorinostat | 2015 |